Seeking Druggable Targets and Technologies to Monitor Glomerular Filtration Rate in Chronic Kidney Disease and Acute Kidney Injury

Johnson & Johnson, a global pharmaceutical company with cutting-edge capabilities in drug development and a history of successful academic collaborations wishes to identify druggable targets in Chronic Kidney Disease and Acute Kidney Injury.

Research Interests

• Chronic Kidney Disease: Mechanisms of action that reduce proteinuria by enhancing podocyte/endothelial integrity, reduce renal inflammation/fibrosis, and/or enhance tissue regeneration
• Acute Kidney Injury: Opportunities associated with clinical stage assets are of high interest
• Acute Kidney Injury: Mechanism of actions improving mitochondrial dysfunction and/or stimulation of regenerative repair, technologies that enable monitoring of real time glomerular filtration rate

Developmental Stages of Interest

• Research at basic level through to clinical phase II is within scope
• Validation through cell or animal models is encouraged, but research before this stage is also of interest

Out of Scope

• Agents that act primarily by weight loss or glucose reduction and primarily indicated for diabetes or obesity
• Diabetic Kidney Disease mechanisms of actions that primarily act via changes in hemodynamics or weight loss

Jurisdictions of Interest

Only submissions from universities and academic institutions in Europe, Africa and the Middle East will be considered.

Submission Information

Submission of one-page research briefs (approx 200 ‑ 300 words) plus any extra applicable information is encouraged.